USD 13.84
Price
-0.96
(-6.49%)
Day Change
|
|
---|
IZTC, the overall quality is not quite good (Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
Quality Factors |
|
33% |
In Recommendations? | Not in any sections |
Select Rate | 0.00 From 30 days period |
Watch Rate | 0.00 From 30 days period |
Social Score | 12 |
Magic Formula Rank by ROA |
N/A
|
Magic Formula Rank by ROE |
N/A
|
Magic Formula Rank by ROIC |
N/A
|
Price | 13.84 |
PBV / Sector |
0.00 / 1.90
|
Earning Per Share | 0.00 |
PE / Sector |
N/A / 17.57
|
PEG or PE/Growth / Sector |
N/A / 5.48
|
Average 1M Daily Value |
0.64 M
GREAT
|
Average 1W Daily Value |
0.84 M
GREAT
|
Timing Factors |
|
57% |
Financial Health |
|
31% |
Ability to Make Profit |
|
37% |
Return to Investors |
|
4% |
Registration Details |
Analyze Date | 2024-11-27 20:29:21 |
Symbol | IZTC |
Name | INVIZYNE TECHNOLOGIES INC. COMMON STOCK |
Sector | Healthcare >> Biotechnology |
Market | NASDAQ |
Listed Shares | 0.00 |
Par Value | N/A |
Calculated From | YearEnd |
Sign | N/A |
Market Cap (M.USD) / Sector Average | 0.00 / 3,618.74 |
News, Concensus, ... |
Estimation Consensus | See at WSJ.com |
Full details | See at WSJ.com |
Chart | See in Chart feature |
News | See at Yahoo Finance |